PLX

Protalix BioTherapeutics, Inc. Common Stock

2.86

USD

+0.29

+11.28%

Nov 10, 15:59 UTC -5

Closed

After-Market

2.87

+0.01

+0.35%

Protalix BioTherapeutics, Inc. Common Stock (PLX) Earnings

PLX Earnings Reports

Positive Surprise Ratio

PLX beat 22 of 42 last estimates.

52%

Next Report

Date of Next Report

Mar 16, 2027

Estimate for Q4 26 (Revenue/ EPS)

$16.27M

-$0.01

Implied change from Q3 26 (Revenue/ EPS)

-25.82%

-120.00%

Implied change from Q4 25 (Revenue/ EPS)

+78.34%

-85.71%

Protalix BioTherapeutics, Inc. Common Stock earnings per share and revenue

On Nov 10, 2026, PLX reported earnings of 0.05 USD per share (EPS) for Q3 26, beating the estimate of -0.03 USD, resulting in a 265.02% surprise. Revenue reached 21.93 million, compared to an expected 12.53 million, with a 75.03% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.01 USD, with revenue projected to reach 16.27 million USD, implying an decrease of -120.00% EPS, and decrease of -25.82% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

CalciMedica, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$1.30

Actual

-$0.72

Surprise

+44.64%

FAQ

What were Protalix BioTherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Protalix BioTherapeutics, Inc. Common Stock reported EPS of $0.05, beating estimates by 265.02%, and revenue of $21.93M, 75.03% above expectations.

How did the market react to Protalix BioTherapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Protalix BioTherapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 16, 2027.

What are the forecasts for Protalix BioTherapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Protalix BioTherapeutics, Inc. Common Stock is expected to report EPS of -$0.01 and revenue of $16.27M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.